Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Learn how ultrafine bubble showers can improve eczema symptoms by reducing inflammation and enhancing skin barrier proteins.

At this week’s American Chemical Society Spring meeting, Galderma SA reported the discovery of novel, oral and selective macrocyclic inhibitors of protein kinase C θ (PKCθ) for the potential treatment ...

Discover a study that investigated how understanding atopic dermatitis endotypes is crucial for advancing personalised ...

Asthma and atopic dermatitis are chronic inflammatory diseases of the airways and the skin, respectively, which affect hundreds of millions of children and adults globally. Most patients with asthma ...

Bubble baths might be soothing soaks, but bubble showers could be the next thing in keeping the skin clean. An Osaka ...

PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class ...